Tyra Biosciences granted IND clearance from FDA for Phase 2 study of Tyra-300

TIPRANKS10-28

Tyra Biosciences (TYRA) announced that the FDA cleared its Investigational New Drug application for Tyra-300 allowing the company to proceed with a...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment